Tianjin Medical University Second Hospital

This trial is testing whether adding a template lymph node dissection (removing nearby lymph nodes) to the standard surgery for high-risk upper tract urothelial cancer helps patients live longer without the cancer returning. About 150 participants will be randomly assigned to get…

This study compares two surgical approaches for high-risk kidney cancer: a standard limited lymph node removal versus a more thorough 'template' dissection. Researchers want to see if the more extensive surgery helps prevent cancer from returning and improves survival. About 220 …

This study tests whether the immunotherapy drug toripalimab can prevent kidney cancer from coming back in high-risk patients who have had their kidney removed. Researchers will also check if a blood test for minimal residual disease (MRD) can predict which patients benefit most. …

This study tests whether a urine DNA test can help guide when to stop immunotherapy in people with a very high-risk type of bladder cancer that cannot be fully removed by surgery. About 53 participants will receive immunotherapy and then be monitored with urine tests and scans. I…

This phase 2 trial is testing two drugs—tislelizumab and disitamab-vedotin—given before surgery for a rare cancer of the upper urinary tract (UTUC) that is HER2-positive and high-risk. The goal is to see if the combination can shrink or eliminate tumors, making surgery more effec…

This phase II trial tests whether a combination of tislelizumab (an immunotherapy) and nab-paclitaxel (a chemotherapy drug) can treat renal pelvic cancer while allowing patients to keep their kidney. About 35 adults with early-stage cancer will receive the drugs, and if the tumor…

This phase 2 trial is testing a combination of two drugs—sacituzumab tirumotecan and tagitanlimab—in people with aggressive variant or neuroendocrine prostate cancer that has progressed after prior treatments. The study aims to see if the combo can shrink tumors and delay disease…

This phase 2 trial tests a three-part approach for advanced kidney cancer: first, a procedure to block blood flow to the tumor, then two drugs (toripalimab and axitinib) before surgery, followed by more toripalimab after surgery. The goal is to see if this makes surgery more succ…

This study tests an experimental drug called tunlametinib in 15 people with advanced solid tumors (not melanoma) that have a mutation in the NRAS gene and have not responded to other treatments. The drug is taken as a capsule twice a day in 21-day cycles. The main goal is to see …

This study looks at whether a simple urine test for tumor DNA can tell which bladder cancer patients truly need a second surgery after their first tumor removal. About 196 adults with non-muscle-invasive bladder cancer will be randomly assigned to have their repeat surgery decisi…

This study is testing whether a simple urine test that looks for cancer DNA can help decide when patients with high-risk bladder cancer need a cystoscopy (a camera exam of the bladder). Cystoscopy is effective but uncomfortable and can cause infections. The goal is to safely redu…

This study looks at whether a simple urine test can detect leftover cancer after initial surgery for high-risk bladder cancer. The goal is to help doctors decide who truly needs a second surgery, avoiding unnecessary procedures and their risks. About 60 adults with high-risk non-…

This study is testing a new liquid biopsy that uses blood and urine samples to help diagnose, monitor treatment, and predict recurrence in people with urothelial carcinoma (a type of bladder cancer). Researchers will enroll 300 participants and compare the liquid biopsy results w…